Spots Global Cancer Trial Database for Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer
Official Title: A Phase 2 Study of Icotinib With Concurrent Radiotherapy vs. Pemetrexed+ Carboplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer With Epidermal Growth Factor Receptor ( EGFR) Mutation
Study ID: NCT02407366
Conditions
Study Description
Brief Summary: The current standard of care for unresectable locally advanced non-small-cell lung cancer (NSCLC) is a combination of chemotherapy and thoracic radiotherapy (TRT). The standard regimens consist of platinum-based doublet chemotherapy.Icotinib(BPI-2009, Conmana) is the first self-developed small molecular drug in China for targeted therapy of lung cancer.Icotinib is a novel oral quinazoline compound that has proven survival benefit in Chinese patients with lung cancer,especially in EGFR mutation lung cancer. This randomised, multi-center, controlled trial is designed to assess the efficacy and safety of icotinib with concurrent radiotherapy versus pemetrexed + carboplatin with concurrent radiotherapy in inoperable stage III non-small cell lung cancer with EGFR mutation, the primary endpoint is progression-free survival.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The people's Hospital of the Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China
Contact Details
Name: GuoSheng Feng, MD
Affiliation: The People's hospital of Guangxi Zhuang Autonomous
Role: STUDY_CHAIR
Name: Yuan Liang, MD
Affiliation: Guangxi Department of Public Health
Role: STUDY_CHAIR
Name: Lin Hui, MD
Affiliation: The People's hospital of Guangxi Zhuang Autonomous
Role: STUDY_CHAIR
Name: HeMing Lu, MD
Affiliation: The People's hospital of Guangxi Zhuang Autonomous
Role: STUDY_CHAIR
Name: ChangJie Huang, MD
Affiliation: Nanning Second People's Hospital
Role: STUDY_CHAIR
Name: GuiSheng LI, MD
Affiliation: Liuzhou Workers Hospital
Role: STUDY_CHAIR
Name: HaiXin Huang, MD
Affiliation: Liuzhou Workers Hospital
Role: STUDY_CHAIR
Name: HaoLin Yan, MD
Affiliation: First People's Hospital of Yulin
Role: STUDY_CHAIR
Name: Ping Liang, MD
Affiliation: Guangxi Ruikang Hospital
Role: STUDY_CHAIR
Name: BingQiang Ni, MD
Affiliation: The People's hospital of LiuZhou
Role: STUDY_CHAIR
Name: YanRong Hao, MD
Affiliation: The People's hospital of Guangxi Zhuang Autonomous
Role: STUDY_CHAIR
Name: XianBin Yuan, MD
Affiliation: The People's hospital of Guangxi Zhuang Autonomous
Role: STUDY_CHAIR
Name: Shan Gao, MD
Affiliation: The People's hospital of Guangxi Zhuang Autonomous
Role: STUDY_CHAIR
Name: Xia Wu, MD
Affiliation: The People's hospital of Guangxi Zhuang Autonomous
Role: STUDY_CHAIR
Name: XiangLi Lai, MD
Affiliation: The People's hospital of Guangxi Zhuang Autonomous
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
